Details for Patent: 8,580,304

Which drugs does patent 8,580,304 protect, and when does it expire?

Patent 8,580,304 protects MEKINIST and is included in one NDA.

Protection for MEKINIST has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-four patent family members in thirty-seven countries.

Summary for Patent: 8,580,304

Title:	Pharmaceutical composition
Abstract:	Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same.
Inventor(s):	Douglas J. DeMARINI, Francisco Henriquez, Ngocdiep T. LE, Lihong Wang
Assignee:	Novartis Pharma AG , GlaxoSmithKline LLC , Novartis Pharmaceuticals Corp
Application Number:	US13/330,949
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,580,304
Patent Claim Types: see list of patent claims	Composition; Compound; Process; Dosage form;

error: insufficient information

Drugs Protected by US Patent 8,580,304

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-001	May 29, 2013		RX	Yes	No					Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-002	May 29, 2013		DISCN	Yes	No					Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes					Y

International Family Members for US Patent 8,580,304

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	084102
Argentina	122185
Australia	2011349422
Brazil	112013015602
Canada	2822701